Clinical Trial Update: Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC [Phase 3]

View source ↗

Summary

Phase III study of SY-5007, a RET inhibitor, in RET fusion-positive non-small cell lung cancer is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SY-5007 (SY-5007)

Snippet

Sponsor: Shouyao Holdings (Beijing) Co. LTD | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING